On Wednesday, October 11, 2023, we teamed up with Cyberport, HKMHDIA, and UMP Innov Centre to host the “Bright Ideas, Strong Barriers: A Patenting Masterclass” seminar, both in-person and online. Jennifer, our Managing Director, and Pauli, our Principal, took the stage and delivered presentations on the fundamentals of intellectual property (IP) and the challenges faced in MedTech/Healthcare innovation within the GBA and China.

We were privileged to have a distinguished panel of experts who generously shared their experiences and insights on the topic of “MedTech Innovations and Intellectual Property Protection.” Our esteemed panelists included Ronnie Li from UMP Healthcare Group as the moderator, Dr. Lydia Leung from HKMHDIA and Belun Technology, Mr. Justin Chan from Gense Technologies, Ms. Kim Chow from LinkAIQ, and our very own Managing Director, Ms. Jennifer Che.

At Eagle IP Limited, our mission is to assist both local and foreign inventors in safeguarding their creations and business endeavors. Through seminars like these, we aim to raise awareness about the importance of IP in the technology industry. We eagerly anticipate organizing more IP workshops and events for our community!






我們過去活動

Recommended Insights

China Patent Office (CNIPA) Releases More Details About Patent Term Adjustment (PTA) in the Draft Examination Guidelines

2021年10月19日
The new 4th Amendment of the Chinese Patent Law came into effect on June 1, 2021. Right before that date, the Chinese Patent Office (“CNIPA”) released some “Interim Measures” to give us a taste of what was to come, though they have yet to released the actual Implementation Rules. Two months later, CNIPA finally released […]

China’s Newest Examination Guidelines: Novelty and Inventive Step for Compounds (Part II)

2021年4月29日
This is Part II of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]

Can Post Filing Data Overcome Inventive Step in China?

2018年11月19日
Since 2010, the Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that discusses […]

Breaking News: Newest Draft Amendment to the Chinese Patent Law Available for Public Comment

2020年7月10日
Finally, after more than a year since the last draft amendment came out in 2019, a new draft has been submitted to the National People’s Congress Standing Committee for deliberation on June 28, 2020. The newest version is now published for public comments until August 16, 2020. As a whole, these proposed changes address a […]
Top crossarrow-right